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were each strongly enhanced (up to 5 fold) by ultrasound exposure. (** p<0.05 vs. acous- 
tic lipid + DNA) 
Conclusions: Ultrasound in conjunction with ultrasound-reflective lipoplexes improves 
gene transfer. Acoustic liposomes conjugated to antibodies have independently been 
shown to target to vascular disease sites in vivo; thus, using ultrasound, it becomes fea- 
sible to both identify a disease site and activate a therapeutic agent in situ. 
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814-1 Bradycardia and Abnormal Calcium Handling in 
Transgenic Mice Overexpressing Juntin 
Mveono-Chan Cho, Jin-Sook Kwon, So-Young Choi, Tae-Jin Youn, Dong-Woon Kim, 
Chang-Soc Hong, Do-Han Kim, Chungbuk National University Hospital, Cheongju, South 
Korea, Kwangju Institute of Science and Technology, Kwangju, South Korea. 
Background; Junctin is integral membrane protein that co-localize with the ryanodine 
receptor (RyR), calsequestrin and triadin at the junctional SR membrane in cardiac and 
skeletal muscle. 
Methods; To investigate physiological role of junctin in excitation-contraction coupling, 
transgenic mice overexpressing junctin were developed. 
Results; Transgenic (TG) mice exhibited 14-fold higher levels of junctin in myocardium 
and survived into adulthood, but developed cardiac hypertrophy of variable severity from 
mild increase in mass to generalized cardiac hypertrophy with early death. Junctin TG 
mice had a normal LV end-diastolic dimension and systolic function on echocardio- 
graphy. In two transgenic lines (Lines t 22 and 129) having higher junctin expression, RV 
failure with marked RA and RV dilatation developed and subsequently resulted into early 
death. In junctin TG mice, ANF expression was increased in all cardiac chambers. Micro- 
scopic examination of the TG heart revealed general cardiac hypertrophy with increased 
collagen contents and thrombus in both atria. Ultrastructural analysis demonstrated irreg- 
ular Z-band intervals, loss of mitochondrial membrane or cisternae. The HR (375±51/ 
rain) of the TG mice was less than that (440±61/min) of their littermates (p<0.01). Brady- 
cardia with intermittent ventdcular premature beats was observed in the young TG mice. 
In TG heart, the expression levels of triadin and ryanodine receptor were significantly 
decreased and protein level of dihydropyridine receptor was increased without significant 
changes in other E-C coupling proteins. The capacitance of TG cardiomyocytes 
(313.8±15.2pF) was similar to that (324.6±16.7pF) of wild-type. Ca 2+ release from SR in 
single cardiomyocytes did not appear to be altered in TG mice. On the other hand, L-type 
Ca 2+ current density in the ventricular cardiomyocyte was significantly increased, which 
could cause the observed prolonged action potential durations and bradycardia. 
Conclusion; These results suggest that regulation of junctin expression must play an 
important role in proper heart function. 
11:15 a.m. 
814-2 Gene Therapy Using a Novel Method of Delivery: 
Continuous Perimuscular Infiltration 
Ariel Roouin, Samy Nitecki, Irit Rubinstein, Edmond Sabo, Zaid A. Abassi, Meira Frank, 
Nina S. Levy, Orit Lache, Aharon Hoffman, Andrew P. Levy, Rambam Medical Center, 
Haifa, Israel, Technion - israel Institute of Technology, Haifa, Israel. 
Introduction: Gene therapy with angiogenic cytokines that induce the development of 
collaterals in ischemic tissue are usually given by a single intra-artedal or intra-muscular 
(IM) injection. Naked DNA has no immunological side effects however its infectivity is 
usually low. Our aim was to evaluate the usefulness of a new method for gene therapy -
continuous infiltration of naked-DNA and compare it with IM in augmenting collateral for- 
mation and tissue perfusion in a mouse unilateral ischemic hindlimb model. 
Methods: The left lilac artery of C57 mice was ligated in two pieces and cut. An osmotic 
infusion pump containing a placebo or VEGF in different concentrations was implanted 
intra-abdominaly and the outlet tube from the pump fenestrated and tunneled into the left 
quadriceps muscle. This novel system delivers perimusculary the tested drug in a con- 
stant rate of 1 i~L/hour for 7 days. Ischemic (left)/normal (dght) limb blood flow was mea- 
sured using a laser Doppler blood flow meter and was monitored every 3-days. 
Results: The flow restoration using continuous infiltration was faster and more complete 
than with IM injection (p<0.05). For the continuous infiltration group; auto-amputation due 
to severe ischemia was observed only in the placebo group (33% Vs. 0%). VEGF 
resulted in a faster and more complete restoration of blood flow. Furthermore, the resto- 
ration of blood flow by VEGF was dose dependent. By day 7 the blood flow was almost 
complete for the group treated with 500 pg VEGF, while in the placebo group the flow 
returned to normal only after 21 days (p<0.05). Vessel density using smooth muscle ectin 
(arteriogenesis) and factor VIII (angiogenesis) were higher in the VEGF continuous infil- 
tration group. PCR demonstrated the plasmid infiltrated only in the ischemic leg and in 
the liver 
Conclusions: Our results demonstrate that using a continuous perimuscular infiltration 
for 7-days of naked-DNA encoding VEGF via an osmotic pump is associated with muscle 
and limb salvage due to the rapid and successful restoration of blood flow. The flow rate 
restoration was faster and more comlete than the traditional IM method. This method 
could serve as another option for gene therapy delivery. 
11:30 a.m, 
814-3 Distinct Expression Patterns of Connexin$ in the 
Chambers and Conduction System of the Human Fetal 
Heart 
Rivaz A. Kaba. Steven R. Coppen, Emmanuel Dupont, Jeremy N. Skepper, Suzy Elneil, 
Magdi H. Yecoub, Stephen Rothery, Nicholas J. Severs, National Heart & Lung Institute, 
imperial College, London, United Kingdom, University of Cambridge, Cambridge, United 
Kingdom. 
Background: Gap junctions have been shown to play an important role in the structural 
and electrophysiological development of the mouse heart. This study was undertaken to 
determine the specific expression pattern of three connexin isotypes, conoexins 40, 43 
and 45, in the atria and ventricles of the 9-week human fetal heart. Methods: Five heads 
of 9-week old fetuses obtained from surgical termination of pregnancy were rapidly fro- 
zen for examination by immunocytochemistry and Western blotting. Confocal microscopy 
was employed to study the distribution of immunolabeled connexins 40, 43 and 45 in the 
atria and ventricles. Double labeling techniques were applied to examine the spatial rela- 
tionship of expression of pairs of connexin isotypes. Hearts were also analyzed by West- 
em blotting for connexins 43 and 40 after separating the atda and the ventricles. Results: 
The predominant connexin in the 9-week human fetal atrium was connexin40, which was 
co-expressed with lower levels of connexin45. Connexin43 (the major human adult car- 
diac connexin) was virtually undetectable in the atria. In the ventricles, by contrast, 
connexin43 predominated while connexin45 was found at similar levels to those in the 
atria. Connexin40 was far less abundant in the ventricles than in the atria. Western blot 
analysis of connexins 43 and 40 confirmed the results obtained by the corresponding 
immunoconfocal studies. In regions of the early ventricular conduction system, from the 
commencement of the bundle branches through to the trabecular layer, all three connex- 
ins were prominently expressed. Conclusions: Our findings show that different regions 
(atria, ventricles and central conduction system) of the eady human fetal heart display 
discrete connexin profiles. Enhanced connexin expression acts as a marker of the form- 
ing ventricular conduction system as early as 9-weeks in the human fetus. The distinct 
pattern of connexin expression between the fetus and adult emphasizes the dynamic 
nature of gap junction expression during morphogenesis of the human heart. 
11:45 a.m. 
814-4 Platelet GPla (G873/873A) and GPIIbllla (leu33/33pro, 
PIA1/PIA2) Glycoprotein Receptor Polymorphisms: An 
Analysis of Functional Effects and Association With 
Risk of Premature Myocardial Infarction 
Ravi K. Sinoh. Hashmik Patel, Peter Braund, Julian Stdbling, Pat Desouza, Suzanne 
Cheng, Alison H. Goodall, Nilesh J. Samani, University of Leicester, Leicester, United 
Kingdom, Roche Molecular Systems, Alameda, California. 
Background There is controversy about the role of platelet glycoprotein receptor poly- 
morphisms, GPla (G873/873A) and GPIIbllla (leu33/33pro), in increasing risk of MI. The 
purpose of this study was to examine functional correlates of the two polymorphisms and 
investigate their role in determining risk of premature MI (<50 years), a situation in which 
any increased thrombotic tendency is likely to be most manifest. 
Methods 200 cases with a validated premature MI (mean event age 42.7±5.4 years) and 
200 age, sex and smoking status matched controls were studied. All cases were stable 
and at least 3 months beyond their thrombotic event. DNA was genotyped for the GPta 
(G873/873A) and GPIIbllla (leu33/33pro) polymorphisms by PCR. Flow cytometric analy- 
sis using fresh citrated whole blood was used to quantify GPla and GPIIbllla receptor 
expression and fibdnogen binding to the GPIIbllla receptor in response to agonist stimu- 
lation (ADP and thrombin) using CD49b, CD41 and anti-fibrinogen monoclonal antibod- 
ies respectively. Platelet volume, count and plasma fibrinogen were also measured, 
Results The GPla polymorphism demonstrated a gene dosage effect on the expression 
of the receptor on the platelet surface in both cases and controls (mean florescence 
index G/G vs G/A vs NA = 3.77_+0.18, 5.05+0.23, 5.861-0.45 and 3.98_+0.25, .27±0.27, 
6.13_+0.25 respectively, all p-values < 0.01). However, there were no significant differ- 
ences between cases and controls for genotype distributions for either the GPla (G/G vs 
G/A vs A/A = 37, 43, 20 and 41,43, 17% respectively, p = 0.68) or GPIIbllla (leu/leu vs 
leu/pro vs pro/pro = 71, 27, 1 and 68, 30, 2 respectively, p= 0.76) polymorphisms. The 
GPIIbllla polymorphism did not influence either receptor expression or fibrinogen bind- 
ing, even taking into account platelet volume, count and fibrinogen level. 
Conclusions The GPla (G873/873A) polymorphism has a significant gene dosage influ- 
ence on the expression of the receptor on the platelet surface. However, this does not 
lead to an increased risk of premature MI in subjects carrying the 873A allele. The GPllb/ 
Ilia (leu33/pro33) polymorphism does not modify either expression or activity of the 
receptor or influence risk of early MI. 
